ANTIGENIC REGIONS OF TUMOUR-LIBERATED PARTICLES (TLP) COMPLEXES AND ANTIBODIES AGAINST THEM

Abstract: Peptides comprised within the 100 KDa protein of the TLP complex (i.e., released proteins from tumors) having antigenic activity as well as antibodies thereof, able to react with TLP for diagnostic and clinical purposes.

Description: ANTIGENIC REGIONS OF TUMOUR-LIBERATED PARTICLES (TLP) COMPLEXES AND ANTI¬ BODIES AGAINST THEM. SPECIFICATION This invention relates to peptide regions of 5 the human TLP proteic complexes (proteins released from tumors) with antigenic activity, as well as to antibodies reacting with such proteins, to be used for diagnostic and clinical purposes. TLP complexes are proteic complexes present in 0 human tumor cells, particularly in lung carcinoma cells; among the TLP proteins a 100 KDa protein is described (Tarro G., "Oncology", 40, 248- 253, 1983) . TLPs are isolated from tumoral tissues, as described in the EP 283 433, the description thereof is incorporated 5 herein as reference. It is very useful to have diagnostic assays to identify such complexes, or fractions thereof, from crude lung extracts. Author's attempts to obtain specific antibodies against whole TPL's did not succeed. Therefore it is 0 important to identify TLP antigenic regions (epitopes) and raise antibodies thereof, in order to obtain specific reactants. The author of the present invention has identified peptide sequences of the TLP 100 KDa protein 5 having antigenic activity, has obtained specific antibodies and has demonstrated that said antibodies reacted specifically with TLPs from lung carcinomas. Accordingly, an object of this invention are TLP antigenic regions being able to induce antibodies 0 anti-TLP complexes. Preferably said regions comprise a peptide having the amino acid sequence comprised within the sequence of the 100 KDa protein of TLP. According to a preferred embodiment of the invention, said regions comprise a peptide having at 5 least one of the amino acid sequences listed at the end of the specification as Seq ID Nl, Seq ID N2 or Seq ID N3. Preferably said peptides are of synthetic origin, alternatively of natural source. In a further embodiment of the invention, said peptide comprises a cystein residue at either its carboxylic or aminic terminal group, and a molecule carrier, covalently bound to said residue; preferably said molecule carrier is hemocyanin, most preferably said hemocyanin is obtained from oysters. Another object of the invention are specific reactants, able to detect TLP proteins; preferably said reactants comprise antibodies, more preferably said antibodies recognize peptide fractions comprising at least one of the amino acid sequences listed at the end of the specification as Seq ID Nl, Seq ID N2 or Seq ID N3. A further object of the invention are diagnostic kits to detect TLP from samples comprising the antibodies of the invention as specific reactants. Another object of the invention is a method to detect TLP complexes from samples, comprising the steps as follows: -to immunoprecipitate said sample with a first amount of the serum anti-TLP; -to evidentiate said TLP complexes from said immunoprecipitated material by reacting the same with a second amount of said serum anti-TLP, and with revealing means of said reaction. This invention will be described in the following with reference to some explanatory, but not limiting examples, to which are related the annexed figures, wherein: Fig. 1 shows some graphics of RIA immunologic assays of serum samples from 4 rabbits immunized with the peptides described in Seq ID Nl, N2 and N3 (A, B, C(419) and D(428) ; Fig. 2A shows a direct immunoblot, using the sera 419 (1) and 428 (2), as well as previously immunized sera (4-6) on samples of lung extracts; Fig. 2B shows an immunoblot wherein the extracts have been previously immunoprecipitated using the 419 and 428 sera; and Fig. 2C shows an immunoblot wherein the extracts heve been previously immunoprecipated, as described in the Example 3. EXAMPLE 1 Detection and Synthesis of Peptides of the Tip Protein The TLP complex is isolated from lung carcinoma extracts, as described in the EP 283 443. The protein is blocked ar the amino terminal group and accordingly digested by V8 protease from Staphylococcus aureus, using known techniques. One of the obtained peptide fragments shows the sequence as follows: XaaXaaArgThrAsnLysGluAlaSerlle. Two synthetic peptides are synthetised, using the solid phase method, by means of a 430 peptide synthetizer from Applied Biosystems, as described by Bodanszky M., Springer Verlag, New York, N.Y., 1984, having the sequences as shown in the table 1 herebelow: TABLE 1 5'-ArgThrAsnLysGluAlaSerIleCys-3' 5'-CysArgThrAsnLysGluAlaSerIle-3' The product identity and purity are confirmed by an analysis of amino acids and HPLC (through a high pressure liquid chromatography procedure) . By using the method described in "Laboratory Techniques in Biochemistry and Molecular Biology" by M.H.V. Van Regermortel, J.P. Brian, S.Muller and S. Plau, Elseviers Publisher, Amsterdam, The Netherlands, 1988, the peptides are linked through the cystein sulphydryl end groups to the lysine lateral residue of oyster emocyanin, using the maleinhydrobenzoyl-N- hydrosuccinimide esther (MBS) as reactant. EXAMPLE 2 Immunization Four rabbits are injected subcutaneously with 0.5 g of a mixture of the complexes of the Example 1 in 1.5 ml of PBS (phosphate salt buffer) and with 0.5 ml of complete Freund's adjuvant. Incomplete adjuvant as burst injection is administered at two week intervals. Serum samples are picked up each two weeks and subjected to RIA, as described in "Laboratory Techniques in Biochemistry and Molecular Biology", 4th edition, by T. Chard, Elsevier Science Publishers, Amsterdam, The Netherlands, 1990, using 96 well microtitration plates, covered with a known concentration of synthetic peptides as antigens. The plates are incubated at different serum dilution levels, then washed out and treated with iodinized protein A in order to detect the presence of specific in the serum. The fig. 1 shows the resulting data of the sampled sera from the four immunized rabbits as above. All sera show an appr. 15,000 cpm radioactivity peak at 1:1,000 dilution, and are able to react also at higher dilutions. The basic levels, obtained with pre- immunized sera as controls, are in the range from 1,000 cpm up to 1,500 cpm, showing a 10:1 ratio at 1:1,000 dilution. The background signal ratio is higher than 20:1 for the 419 and 428 sera. EXAMPLE 3 Reaction with Sera The 419 and 428 sera are assayed using lung extracts which are obtained, as described in the EP 283 443, by three patients suffering a lung epidermoidal- type carcinoma or an adenocarcinoma, according to "International Classification of Diseases for Oncology, 2nd edition 1990, edited by C. Percy, V. Van Holte and C. Muir, WHO, Geneva (fig.2A) . Aliquots of said extracts (1 and 4 = B.C.; 2 and 5 = S.G. ; 3 and 6 = M.R.) are solubilized in detergent solutions and separated by an electrophoresis procedure according to known methods by polyacrylamide gels. A direct immunoblot is then carried out using the 419 (1) and 428 (2) sera. Two non specific appr. 55 KDa and 35 KDa proteic bands are detected, which are present also when the pre-immunized sera (4-6) are used. Then, the extract are immunologically precipitated with the 419 and 428 sera, using existing techniques, as described by E. Harlow and D. Lane, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y (1988); the i munological precipitated material is separated on gel and used for immunoblot with the same sera. Fig. 2 shows the results, wherein a 100 KDa specific band is detected in all extracts, when assayed both with the 419 serum (1-3) and the 428 serum (4-6) . The assayed extract in 1 and 4 shows a very large TLP protein amount. In order to establish whether the reaction is specific, the following control tests are carried out, as shown in fig. 2C, wherein: line 1 is the BC patient's serum, wherein the 419 immunized serum is used either to immunoprecipitate and to immunoblot; line 2 is obtained using a pre-immunized serum for the immunoprecipitation step and the 419 serum for the immunoblot; line 4 results from using the 419 serum, preincubated with the peptide of Seq ID Nl, for the precipitation step and the 419 serum for the immunoblot; line 5 is obtained by using the 419 serum for the immunoprecipitation step and the preimmunized serum for the immunoblot. The results confirm that the appr. 100 KDa proteic band specifically reacted with the immunized 419 serum. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Istituto Farmacoterapico Italiano SpA (B) STREET: Via Paolo Frisi 21/23 (C) CITY: Rome (E) COUNTRY: Italy (F) POSTAL CODE (ZIP) : 00197 (A) NAME: Giulio Tarro (B) STREET: c/o IFI Via Paolo Frisi 21/23 (C) CITY: Rome (E) COUNTRY: Italy (F) POSTAL CODE (ZIP) : 00197 (ii) TITLE OF INVENTION: Antigenic regions of TLP complexes and antibodies against the sames (iii) NUMBER OF SEQUENCES: 3 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO) (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: IT RM92/A000506 (B) FILING DATE: 03-JUL-1992 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (F) TISSUE TYPE: Lung carcinoma (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Arg Thr Asn Lys Glu Ala Ser lie 1 5 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (F) TISSUE TYPE: Lung carcinoma (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Gly Ser Ala Xaa Phe Thr Asn 1 5 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (F) TISSUE TYPE: Lung carcinoma (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Asn Gin Arg Asn Arg Asp 1 5

Claims: CLAIMS 1. TLP antigenic regionsibeing able to induce antibodies anti-TLP complexes. 2. TLP antigenic regions according to claim 1, comprising a peptide having the amino acid sequence comprised within the sequence of the 100 KDa protein of TLP. 3. TLP antigenic regions according to claim 2, comprising a peptide having at least one of the amino acid sequences listed at the end of the specification as Seq ID Nl, Seq ID N2 or Seq ID N3. 4. TLP antigenic regions according to claim 3, wherein said peptide is of synthetic origin. 5. TLP antigenic regions according to claim 3, wherein said peptide is from a natural source. 6. TLP antigenic regions according to claim 4, wherein said peptide comprises a cystein residue at either its carboxylic or aminic terminal group, and a molecule carrier, covalently bound to said residue. 7. TLP antigenic regions according to claim 6, wherein said molecule carrier is hemocyanin. 8. TLP antigenic regions according to claim 7, wherein said hemocyanin is hemocyanin from oysters. 9. Specific reactants having the ability to detect the TLP proteins. 10. Specific reactants having the ability to detect the TLP proteins according to claim 9 caracterized in comprising antibodies against TLP. 11. Specific reactants having the ability to detect the TLP proteins according to claim 10, wherein said antibodies recognize peptide fractions comprising at least one of the amino acid sequences listed at the end of the specification as Seq ID Nl, Seq ID N2 or Seq ID N3. 12. Diagnostic kits to detect TLP in samples comprising the antibodies as specific reactants according any of claims from 9 to 11. 13. Method to detect TLP complexes from samples, comprising the steps as follows: - to immunoprecipitate said sample with a first amount of the immunized serum anti-TLP; - to evidentiate said TLP complexes from said immunoprecipitated material by reacting the same with a second amount of said serum anti-TLP, and with revealing means of said reaction.

Inventors: TARRO GIULIO, TARRO, GIULIO
Applicants: IST FARMACOTERAPICO IT SPA, TARRO GIULIO, ISTITUTO FARMACOTERAPICO ITALIANO S.P.A.
Application year: 1993
Main classification: C07K7
IPC codes: A61K39, C07K7, C07K14, C07K16, C12P21, G01N33